India's Patent Policy Needs More Stakeholder Input, US Trade Office Urges
Executive Summary
'Watch List' from USTR also objects to China's definition of 'new drugs'; PhRMA criticizes practices in Canada and Columbia.
You may also be interested in...
Rx Pricing Practices Of US Trading Partners Criticized By Trade Office
US Trade Representative also highlights restrictive patentability criteria in Canada, India and Indonesia in its annual Special 301 report.
Permanent Vaccine Facility Should Be On Standby For Future Pandemics, Moncef Slaoui Says
Operation Warp Speed confirmed the necessity of having a facility on hand to develop and manufacture a vaccine for the next crisis, the outgoing advisor says.
FDA’s COVID-19 Pandemic Plan Calls For Ongoing Clinical Trial Innovation
Broader use of adaptive trial designs and master protocols, checklist-based application review, and enhancement of real-world monitoring of products are among the recommendations of US FDA's COVID-19 Pandemic Recovery and Preparedness Plan (PREPP) report, an effort months in making based on interviews with agency management, staff, and outside stakeholders.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: